CRISPR Therapeutics AG vs AbCellera Biologics Inc.
CRSP and ABCL are evenly matched across key metrics.
🏆 Tale of the Tape
Green = winner in each category. Higher is better except P/E (lower = cheaper).
Fundamentals
| Metric | CRSP | ABCL |
|---|---|---|
| Market Cap | $5.4B | — |
| P/E Ratio | — | — |
| Forward P/E | -14.5x | — |
| P/B | 2.98x | — |
| Dividend Yield | — | — |
| Beta | 1.74 | — |
Quantitative Metrics
| Metric | CRSP | ABCL |
|---|---|---|
| DCF Fair Value | — | — |
| DCF Upside | — | — |
| Piotroski F | 2/9 | 4/9 |
| Altman Z | 7.39 | — |
| Beneish M | — | — |
| FCF Yield | -7.80% | — |
| Net Debt/EBITDA | — | — |
| ROIC | -24.8% | -12.4% |
| WACC | 15.3% | — |
| ROIC – WACC | -40.1pp | — |
| Gross Margin | — | — |
| Net Margin | — | -194.9% |
| Rev Growth YoY | — | 160.6% |
| Sharpe (1Y) | 0.95 | — |
| Max Drawdown 3Y | -64.9% | — |
| FCF Payout Ratio | — | — |
CRSP Price
ABCL Price
ETF Exposure
More Comparisons
Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.
CRSP vs ABCL: Head-to-Head Analysis
CRISPR Therapeutics AG (CRSP) and AbCellera Biologics Inc. (ABCL) represent two companies in the Healthcare sector. Our quantitative Tale of the Tape shows these companies are evenly matched across profitability, valuation, and risk metrics.
In terms of capital efficiency, CRSP generates a return on invested capital (ROIC) of -24.8% compared to ABCL's -12.4%. This suggests ABCL is more effective at deploying capital to generate shareholder returns.
CRSP appears in 5 ETFs tracked by SecuritiesDB, while ABCL appears in 2 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.
Frequently Asked Questions
Which stock is the better investment, CRSP or ABCL?
Our quantitative analysis compares CRSP and ABCL across nine fundamental dimensions. CRSP and ABCL are evenly matched across key metrics. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.
Are CRSP and ABCL correlated?
Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.
How is the Tale of the Tape scored?
The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.